DMC Biotechnologies raises $34 million

December 6, 2021 |

In Colorado, DMC Biotechnologies has raised $34 million to help advance its biobased chemical intermediate, which has applications in home care and human nutrition. 

The Series B funding included investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.

 “Building back better after the pandemic means we need to strengthen domestic manufacturing and improve supply chain resiliency,” Matt Lipscomb, DMC CEO and cofounder, says in a statement. “Biomanufacturing is one critical part of this strategy and DMC is positioned to be a significant part of this change. This financing will accelerate the commercialization of economically attractive and sustainable choices for consumers.” 

Print Friendly, PDF & Email

Category: Chemicals & Materials

Thank you for visting the Digest.